Trevena Inc
NASDAQ:TRVN
Intrinsic Value
Trevena, Inc. engages in the development and commercialization of novel medicines for patients affected by central nervous system disorders. [ Read More ]
The intrinsic value of one TRVN stock under the Base Case scenario is 1.164 USD. Compared to the current market price of 0.381 USD, Trevena Inc is Undervalued by 67%.
Valuation Backtest
Trevena Inc
Run backtest to discover the historical profit from buying and selling TRVN stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Trevena Inc
Current Assets | 35.2m |
Cash & Short-Term Investments | 33m |
Other Current Assets | 2.2m |
Non-Current Assets | 5.4m |
PP&E | 4.9m |
Other Non-Current Assets | 540k |
Current Liabilities | 7.6m |
Accounts Payable | 2.3m |
Accrued Liabilities | 5.2m |
Other Current Liabilities | 10k |
Non-Current Liabilities | 40.7m |
Long-Term Debt | 30.8m |
Other Non-Current Liabilities | 9.9m |
Earnings Waterfall
Trevena Inc
Revenue
|
3.1m
USD
|
Cost of Revenue
|
-1.7m
USD
|
Gross Profit
|
1.5m
USD
|
Operating Expenses
|
-36.7m
USD
|
Operating Income
|
-35.3m
USD
|
Other Expenses
|
-5m
USD
|
Net Income
|
-40.3m
USD
|
Free Cash Flow Analysis
Trevena Inc
TRVN Profitability Score
Profitability Due Diligence
Trevena Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.
Score
Trevena Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.
TRVN Solvency Score
Solvency Due Diligence
Trevena Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Score
Trevena Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
TRVN Price Targets Summary
Trevena Inc
Ownership
TRVN Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
TRVN Price
Trevena Inc
Average Annual Return | -14.11% |
Standard Deviation of Annual Returns | 108.46% |
Max Drawdown | -100% |
Market Capitalization | 6.6m USD |
Shares Outstanding | 18 321 000 |
Percentage of Shares Shorted | 0.62% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Trevena, Inc. engages in the development and commercialization of novel medicines for patients affected by central nervous system disorders. The company is headquartered in Chesterbrook, Pennsylvania and currently employs 43 full-time employees. The company went IPO on 2014-01-31. The firm is focused on developing and commercializing medicines for patients affected by central nervous system (CNS) disorders. The company is developing OLINVYK, a G-protein biased MOR ligand for acute pain in adults. The company is developing TRV027, an angiotensin II type 1 (AT1), receptor selective agonist, for the treatment of acute lung injury contributing to acute respiratory distress syndrome (ARDS), and abnormal blood clotting in patients with COVID-19. The company is developing TRV250, a G-protein biased delta-opioid receptor (DOR), is developed for the treatment of acute migraine. The firm is focused on exploring other formulations, such as transmucosal or transdermal administration for breakthrough or chronic pain, respectively. The firm is in the Phase III clinical program for OLINVO with the enrollment of patients in the ATHENA study, a Phase III, open-label, multicenter study.
Contact
IPO
Employees
Officers
The intrinsic value of one TRVN stock under the Base Case scenario is 1.164 USD.
Compared to the current market price of 0.381 USD, Trevena Inc is Undervalued by 67%.